Development of pseudogout during etanercept treatment.
Josefina
Marcos
M
University Program in Rheumatology, La Plata University, La Plata, Buenos Aires, Argentina. josefinamarcos@hotmail.com
Ana
Cuneo Julia
CJ
Ariel
Vulcano
V
Silvio
Arturi Alfredo
AA
D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002805:Chondrocalcinosis / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept